Massachusetts General Hospital

Sorting 12 by

Accepting patients

REM-422

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
  • MYB mRNA Degrader
  • Phase 1

Accepting patients

Bone Marrow & Kidney Transplant

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

PyramIDH

A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)
  • IDH1 Inhibitor
  • Randomization
  • Phase 3

Accepting patients

LYT-200

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
  • Monoclonal Antibody
  • Galectin-9 Protein
  • Phase 1
  • Has results

Accepting patients

AZD6738

A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
  • Kinase Inhibitor
  • Phase 1

Accepting patients

TCR Engineered Donor T-Cells

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
  • T Cell (Allogeneic)
  • Phase 1
  • Has results

Accepting patients

CLN-049

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
  • Tyrosine Kinase (TK) Inhibitor
  • FLT3 Inhibitor
  • Phase 1

Accepting patients

Assessment for Acquired Pyruvate Kinase Deficiency

Characterization Of Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
  • Laboratory Assay
  • Observational Trial

Accepting patients

MBG453

TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
  • Monoclonal Antibody
  • TIM-3
  • Phase 2

Accepting patients

BMS-986497 (ORM-6151)

Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
  • GSPT1 Degrader
  • CD33
  • Phase 1